TCR molecule and cell targeting KRAS G12V mutation and application of TCR molecule and cell
By developing a TCR binding protein that can specifically recognize KRAS G12V mutant antigen, the drug resistance problem of KRAS G12V mutant tumors in pancreatic cancer treatment has been solved, and effective treatment of pancreatic cancer has been achieved.
Patent Information
- Application Number
- CN202310507375.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
The existing pancreatic cancer treatment methods lack effective means, especially for KRAS G12V mutant tumors, and immunotherapy has drug resistance problems, resulting in poor treatment effect.
A binding protein, including a binding domain that is antigen-specific for the antigen peptide:HLA complex, specifically including the TCR alpha chain and beta chain variable region, is able to specifically recognize and bind antigenic peptides associated with KRAS G12V mutations, using To activate immune effector cells to kill target cells.
It improves the therapeutic effect of KRAS G12V mutant tumors, enhances the killing ability of immune cells to target cells, reduces drug resistance, and provides a new possibility of treating pancreatic cancer.
Smart Images

Figure CN118909132A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to TCR molecules and cells expressing the TCR molecules, especially TCR molecules targeting target cells carrying KRAS G12V mutation and immune effector cells expressing the TCR molecules. The present invention also relates to the therapeutic applications of these TCR molecules and cells. Background Art
[0002] The RAS gene family (HRAS, KRAS, NRAS) is the most common proto-oncogene that can cause tumorigenesis, among which the most common is KRAS mutation (concentrated in codon 12), which is present in about 22-30% of tumors. Although the diagnosis and treatment of pancreatic cancer have made progress in the past decade, the 5-year survival rate of pancreatic cancer is about 9% due to the lack of effective treatment. Current treatments for unresectable pancreatic cancer mainly involve chemotherapy to shrink tumors, but are limited by the emergence of drug resistance. In addition, the success of targeted therapy is also limited. Not only that, pancreatic cancer is also resistant to immunotherapy, which may be partly due to the lack of neoantigen-reactive tumor-infiltrating lymphocytes caused by the low mutation burden of the disease. Research targeting KRAS-G12V TCR-T can effectively improve the current dilemma of no effective treatment for KRAS mutant tumors. Summary of the invention
[0003] In one aspect, provided herein is a binding protein comprising a binding domain having antigenic specificity for an antigenic peptide:HLA complex, the binding domain comprising a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, wherein:
[0004] The antigenic peptide comprises the amino acid sequence VVGAVGVGK (SEQ ID NO: 91);
[0005] The HLA is HLA-A*11:01;
[0006] The CDR3 of the α chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, or 85, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, or 85;
[0007] The CDR3 of the β chain variable region includes the amino acid sequence shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90.
[0008] In some embodiments, the antigenic peptide is VVGAVGVGK (SEQ ID NO: 91) or VVVGAVGVGK (SEQ ID NO: 92).
[0009] In some embodiments, in the α chain variable region: 1) CDR1 comprises the amino acid sequence of SEQ ID NO: 3, CDR2 comprises the amino acid sequence of SEQ ID NO: 4, and CDR3 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; 2) CDR1 comprises the amino acid sequence of SEQ ID NO: 13, CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and CDR3 comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 15; 3) CDR1 comprises the amino acid sequence of SEQ ID NO: 23, CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and CDR3 comprises the amino acid sequence of SEQ ID NO: 25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:25 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:25; 4) CDR1 comprises the amino acid sequence of SEQ ID NO:33, CDR2 comprises the amino acid sequence of SEQ ID NO:34, and CDR3 comprises the amino acid sequence of SEQ ID NO:35, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:35; 5) CDR1 comprises the amino acid sequence of SEQ ID NO:43, CDR2 comprises the amino acid sequence of SEQ ID NO:44, and CDR3 comprises the amino acid sequence of SEQ ID NO:45, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:45; 6) CDR1 comprises the amino acid sequence of SEQ ID NO:53, CDR2 comprises the amino acid sequence of SEQ ID NO:54, and CDR3 comprises the amino acid sequence of SEQ ID NO:55, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO: An amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence shown in NO:55;7) CDR1 comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; 8) CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 75; or 9) CDR1 comprises the amino acid sequence of SEQ ID NO: 83, CDR2 comprises the amino acid sequence of SEQ ID NO: 84, and CDR3 comprises the amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: An amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in NO:85;
[0010] In the beta chain variable region: 1) CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 10; 2) CDR1 comprises the amino acid sequence of SEQ ID NO: 18, CDR2 comprises the amino acid sequence of SEQ ID NO: 19, and CDR3 comprises the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 20; 3) CDR1 comprises the amino acid sequence of SEQ ID NO: 28, CDR2 comprises the amino acid sequence of SEQ ID NO: 29, and CDR3 comprises the amino acid sequence of SEQ ID NO: 30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:30 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:30; 4) CDR1 comprises the amino acid sequence of SEQ ID NO:38, CDR2 comprises the amino acid sequence of SEQ ID NO:39, and CDR3 comprises the amino acid sequence of SEQ ID NO:40, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:40; 5) CDR1 comprises the amino acid sequence of SEQ ID NO:48, CDR2 comprises the amino acid sequence of SEQ ID NO:49, and CDR3 comprises the amino acid sequence of SEQ ID NO:50, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:50; 6) CDR1 comprises the amino acid sequence of SEQ ID NO:58, CDR2 comprises the amino acid sequence of SEQ ID NO:59, and CDR3 comprises the amino acid sequence of SEQ ID NO:60, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:61. NO:60 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:60; 7) CDR1 includes the amino acid sequence shown in SEQ ID NO:68, CDR2 includes the amino acid sequence shown in SEQ ID NO:69, and CDR3 includes the amino acid sequence shown in SEQ ID NO:70, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:70;8) CDR1 comprises the amino acid sequence of SEQ ID NO: 78, CDR2 comprises the amino acid sequence of SEQ ID NO: 79, and CDR3 comprises the amino acid sequence of SEQ ID NO: 80, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 80; or 9) CDR1 comprises the amino acid sequence of SEQ ID NO: 88, CDR2 comprises the amino acid sequence of SEQ ID NO: 89, and CDR3 comprises the amino acid sequence of SEQ ID NO: 90, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 90. ;
[0011] In some embodiments, 1) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 3, CDR2 comprises the amino acid sequence of SEQ ID NO: 4, and CDR3 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 10; 2) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 13, CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and CDR3 comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:15 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:15; in the variable region of the β chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:18, CDR2 comprises the amino acid sequence shown in SEQ ID NO:19, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:20, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:20; 3) in the variable region of the α chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:23, CDR2 comprises the amino acid sequence shown in SEQ ID NO:24, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:25, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:25; in the variable region of the β chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:28, and CDR2 comprises the amino acid sequence shown in SEQ ID NO:29. NO:29, wherein CDR3 comprises the amino acid sequence of SEQ ID NO:30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:30;4) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; 5) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 43, CDR2 comprises the amino acid sequence of SEQ ID NO: 44, and CDR3 comprises the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:45 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:45; in the beta chain variable region, CDR1 includes the amino acid sequence shown in SEQ ID NO:48, CDR2 includes the amino acid sequence shown in SEQ ID NO:49, and CDR3 includes the amino acid sequence shown in SEQ ID NO:50, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:50; 6) in the alpha chain variable region, CDR1 includes the amino acid sequence shown in SEQ ID NO:53, CDR2 includes the amino acid sequence shown in SEQ ID NO:54, and CDR3 includes the amino acid sequence shown in SEQ ID NO:55, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:55; in the beta chain variable region, CDR1 includes the amino acid sequence shown in SEQ ID NO:58, and CDR2 includes the amino acid sequence shown in SEQ ID NO:59. NO:59, wherein CDR3 comprises the amino acid sequence of SEQ ID NO:60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:60;7) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; 8) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:75 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:75; in the beta chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:78, CDR2 comprises the amino acid sequence shown in SEQ ID NO:79, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:80, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:80; or 9) in the alpha chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:83, CDR2 comprises the amino acid sequence shown in SEQ ID NO:84, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:85, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:85; in the beta chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:88, and CDR2 comprises the amino acid sequence shown in SEQ ID NO:89, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:90, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:91 NO: 89, CDR3 includes the amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence shown in SEQ ID NO: 90. ;
[0012] On the other hand, the present invention provides a binding protein, which includes a binding domain, wherein the binding domain includes a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, wherein: 1) CDR1 in the α chain variable region includes the amino acid sequence shown in SEQ ID NO: 3, CDR2 includes the amino acid sequence shown in SEQ ID NO: 4, and CDR3 includes the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 5; CDR1 in the β chain variable region includes the amino acid sequence shown in SEQ ID NO: 8, CDR2 includes the amino acid sequence shown in SEQ ID NO: 9, and CDR3 includes the amino acid sequence shown in SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 10; 2) CDR1 in the α chain variable region includes the amino acid sequence shown in SEQ ID NO: 13, and CDR2 includes the amino acid sequence shown in SEQ ID NO: 14. NO:14, CDR3 comprises the amino acid sequence of SEQ ID NO:15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:15; in the variable region of the beta chain, CDR1 comprises the amino acid sequence of SEQ ID NO:18, CDR2 comprises the amino acid sequence of SEQ ID NO:19, and CDR3 comprises the amino acid sequence of SEQ ID NO:20, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:20; 3) in the variable region of the alpha chain, CDR1 comprises the amino acid sequence of SEQ ID NO:23, CDR2 comprises the amino acid sequence of SEQ ID NO:24, and CDR3 comprises the amino acid sequence of SEQ ID NO:25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:25; in the variable region of the beta chain, CDR1 comprises the amino acid sequence of SEQ ID NO:18, NO:28, CDR2 comprises the amino acid sequence of SEQ ID NO:29, and CDR3 comprises the amino acid sequence of SEQ ID NO:30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:30;4) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; 5) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 43, CDR2 comprises the amino acid sequence of SEQ ID NO: 44, and CDR3 comprises the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:45 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:45; in the variable region of the β chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:48, CDR2 comprises the amino acid sequence shown in SEQ ID NO:49, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:50, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:50; 6) in the variable region of the α chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:53, CDR2 comprises the amino acid sequence shown in SEQ ID NO:54, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:55, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:55; in the variable region of the β chain, CDR1 comprises the amino acid sequence shown in SEQ ID NO:58, and CDR2 comprises the amino acid sequence shown in SEQ ID NO:59. NO:59, wherein CDR3 comprises the amino acid sequence of SEQ ID NO:60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:60;7) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; 8) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:75 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:75; in the beta chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:78, CDR2 comprises the amino acid sequence shown in SEQ ID NO:79, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:80, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:80; or 9) in the alpha chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:83, CDR2 comprises the amino acid sequence shown in SEQ ID NO:84, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:85, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:85; in the beta chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO:88, and CDR2 comprises the amino acid sequence shown in SEQ ID NO:89, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:90, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:91 NO: 89, CDR3 includes the amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence shown in SEQ ID NO: 90. ;
[0013] In some embodiments, in the binding protein: 1) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 2; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 7; 2) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 12; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 17; 3) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 22 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:22 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:22; the β chain variable region includes the amino acid sequence shown in SEQ ID NO:27 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:27; 4) the α chain variable region includes the amino acid sequence shown in SEQ ID NO:32 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:32; the β chain variable region includes the amino acid sequence shown in SEQ ID NO:37 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:37; 5) the α chain variable region includes the amino acid sequence shown in SEQ ID NO:42 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:42 NO:42 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:42; the beta chain variable region includes the amino acid sequence shown in SEQ ID NO:47 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:47;6) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 52, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 52; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 57, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 57; 7) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 62, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 62; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 67; 8) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:72 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:72; the β chain variable region includes the amino acid sequence shown in SEQ ID NO:77 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:77; or 9) the α chain variable region includes the amino acid sequence shown in SEQ ID NO:82 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:82; the β chain variable region includes the amino acid sequence shown in SEQ ID NO:87 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:87. ;
[0014] In some embodiments, the binding protein comprises the TCR α chain and TCR β chain, wherein: 1) the α chain comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 1; the β chain comprises the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 6; 2) the α chain comprises the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 11; the β chain comprises the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 16; 3) the α chain comprises the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: NO:21 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:21; the β chain includes the amino acid sequence shown in SEQ ID NO:26 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:26; 4) the α chain includes the amino acid sequence shown in SEQ ID NO:31 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:31; the β chain includes the amino acid sequence shown in SEQ ID NO:36 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:36; 5) the α chain includes the amino acid sequence shown in SEQ ID NO:41 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:41 NO:41 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:41; the β chain includes the amino acid sequence shown in SEQ ID NO:46 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:46; 6) the α chain includes the amino acid sequence shown in SEQ ID NO:51 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:51;The β chain comprises the amino acid sequence of SEQ ID NO: 56, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 56; 7) the α chain comprises the amino acid sequence of SEQ ID NO: 61, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 61; the β chain comprises the amino acid sequence of SEQ ID NO: 66, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 66; 8) the α chain comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 71; the β chain comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:76 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:76; or 9) the α chain variable region includes the amino acid sequence shown in SEQ ID NO:81 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:81; the β chain includes the amino acid sequence shown in SEQ ID NO:86 or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence shown in SEQ ID NO:86. ;
[0015] In some embodiments, the binding protein is a protein in the form of:
[0016] 1) TCR molecules;
[0017] 2) Antibody molecules; or
[0018] 3) CAR molecule.
[0019] In some embodiments, when T cells expressing the binding protein are incubated with HLA-A*11:01 cells in the presence of the antigenic peptide, or when T cells expressing the binding protein are incubated with HLA-A*11:01 cells expressing the antigenic peptide, the T cells specifically kill the HLA-A*11:01 cells.
[0020] In some embodiments, when T cells expressing the binding protein are incubated with HLA-A*11:01 cells in the presence of the antigenic peptide, or when T cells expressing the binding protein are incubated with HLA-A*11:01 cells expressing the antigenic peptide, the T cells produce INF-γ and / or express CD69, or the amount of INF-γ produced and / or CD69 expressed is increased.
[0021] In some embodiments, the binding protein further comprises a conjugate covalently or non-covalently linked to the binding domain; preferably, the conjugate is a detectable marker, a radioactive isotope or a therapeutic agent.
[0022] In another aspect, provided herein is an isolated nucleic acid molecule encoding the above-mentioned binding protein, α chain variable region, β chain variable region, α chain or β chain.
[0023] In another aspect, provided herein is a vector comprising the above-mentioned nucleic acid molecule.
[0024] In another aspect, provided herein is a host cell expressing the above-mentioned binding protein or comprising the above-mentioned nucleic acid molecule or vector.
[0025] In some embodiments, the host cell is a mammalian cell, preferably a human cell.
[0026] In some embodiments, the host cell is a T cell or a NK cell.
[0027] In some embodiments, the host cell has killing activity against HLA-A*11:01 cells expressing the antigenic peptide VVGAVGVGK (SEQ ID NO: 91) or VVVGAVGVGK (SEQ ID NO: 92).
[0028] In another aspect, provided herein is a pharmaceutical composition comprising: 1) the above-mentioned binding protein, nucleic acid molecule, vector or host cell; and 2) a pharmaceutically acceptable carrier.
[0029] On the other hand, the present invention provides the use of the above-mentioned binding protein, nucleic acid molecule, vector or host cell in the preparation of a medicament for treating a tumor, wherein the tumor expresses the antigenic peptide.
[0030] In another aspect, provided herein is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of the binding protein, nucleic acid molecule, vector, host cell, or pharmaceutical composition described above.
[0031] In some embodiments, the tumor is selected from pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer, endometrial cancer, and ovarian cancer.
[0032] In another aspect, provided herein is a detection kit comprising the above-mentioned binding protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 A representative flow cytometry diagram of pentamer enrichment and sorting of HLA-A*11:01 / KRAS G12V-specific T cells after stimulation is shown.
[0034] Figure 2A CD8 T cells that were not transduced and transduced with different HLA-A*11:01 / KRAS G12V-specific TCRs are shown. + The killing results of T cells on K562-A*11:01 target cells loaded with different antigenic peptides. The peptides loaded in the figure are G12V 9 peptide: VVGAVGVGK (SEQ ID NO: 91), G12V 10 peptide: VVVGAVGVGK (SEQ ID NO: 92), WT peptide: VVGAGGVGK (SEQ ID NO: 93) + VVVGAGGVGK (SEQ ID NO: 94).
[0035] Figure 2B CD8 T cells that were not transduced and transduced with different HLA-A*11:01 / KRAS G12V-specific TCRs are shown. + The results of T cells killing BxPC3 cells overexpressing HLA-A*11:01 and / or KRAS G12V. BxPC3-A1101 is a BxPC3 cell transformed with HLA-A*11:01, BxPC3-A1101-G12V is a BxPC3 cell transformed with both HLA-A*11:01 and KRAS G12V, and BxPC3-A1101-G12D is a BxPC3 cell transformed with both HLA-A*11:01 and KRAS G12D.
[0036] Figure 3 The figure shows the release of IFN-γ after TCR1-transduced T cells were co-incubated with peptide-loaded target cells. BxPC3-A1101 is a BxPC3 cell transduced with HLA-A*11:01, BxPC3-G12V is a BxPC3 cell transduced with KRAS G12V, and BxPC3-A1101-G12V is a BxPC3 cell transduced with both HLA-A*11:01 and KRAS G12V.
[0037] Figure 4A PBMCs transduced with the indicated TCRs and loaded with different concentrations of peptides (10 -11 -10 -6M) target cells (K562-A*11:01) were co-incubated with the cells and the release of IFN-γ was detected by ELISPOT.
[0038] Figure 4B The results show that Jurkat cells transduced with the indicated TCRs were loaded with different concentrations of peptides (10 -11 -10 -6 M) target cells (K562-A*11:01) were co-incubated with the target cells and the expression of CD69 was detected by flow cytometry.
[0039] Figure 4C The results show that Jurkat cells transduced with the indicated TCRs were loaded with different concentrations of G12V-9 or G12V-10 peptides (10 -11 -10 -6 M) target cells (K562-A*11:01) were co-incubated with the target cells and the expression of CD69 was detected by flow cytometry. DETAILED DESCRIPTION
[0040] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0041] The term "or" refers to a single element of the listed optional elements, unless the context clearly indicates otherwise. The term "and / or" refers to any one, any two, any three, any more or all of the listed optional elements.
[0042] The term "about" generally refers to variations within a range of 10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0043] The term "comprising" or "including" means including the stated elements, integers or steps, but does not exclude any other elements, integers or steps. In the text, when the term "comprising" or "including" is used, unless otherwise indicated, it also covers the situation consisting of the stated elements, integers or steps. For example, when it is mentioned that a variable region "comprising" a specific sequence, it is also intended to cover the variable region consisting of the specific sequence.
[0044] The term "major histocompatibility complex (MHC)" is a general term for a group of genes that encode the major histocompatibility antigens of animals. At present, the structures of MHC class I and MHC class II molecules have been completely resolved and belong to the immunoglobulin superfamily. The human MHC is called HLA (humanleukocyte antigen, HLA), that is, human leukocyte antigen. HLA class I molecules mainly include the protein products (heavy chains or α chains) of three functional genes HLA-A, HLA-B, and HLA-C. Each class I HLA heavy chain is paired with β2 microglobulin (β2m) to form a complete MHC class I molecule in the form of a heterodimer. Due to the polymorphism of the genes encoding HLA molecules, the HLA Nomenclature Committee has specified naming principles for specific alleles, the main points of which include: for a certain allele, write the locus name of the gene after the three letters of HLA, connected by a dash in the middle, such as HLA-A; add an asterisk after the locus name, followed by the gene family number described by the allele and the corresponding serological typing as much as possible, followed by a colon (:) and the specific number of the allele, such as HLA-A*02:01. One of the main functions of MHC molecules is to participate in antigen presentation, that is, MHC molecules bind to antigen peptides through their peptide binding grooves to form antigen peptide-MHC complexes (pMHC), and present them on the cell surface for T cells to recognize (through TCR) and trigger immune responses.
[0045] The term "antigenic peptide" refers to a short peptide that can be bound by the peptide binding groove of an MHC molecule (or HLA molecule). The antigen binding groove of the HLA class I molecule is composed of the α1 and α2 domains of the heavy chain (whose extracellular region includes three structures of α1, α2 and α3), and each domain is folded into an α helix and 4 β sheets. Two α helices form the wall of the groove and 8 β sheets form the bottom of the groove. The length of the antigenic peptide suitable for being accommodated in the binding groove is usually 8-11 amino acids. In one specific example, the antigenic peptide is a mutant KRAS protein fragment: VVGAVGVGK (SEQ ID NO: 91). In another specific example, the antigenic peptide is a mutant KRAS protein fragment: VVVGAVGVGK (SEQ ID NO: 92).
[0046] The term "antigenic peptide: MHC complex" or "antigenic peptide: HLA complex" refers to a complex (pMHC) consisting of an MHC molecule and an antigenic peptide, wherein the antigenic peptide is located in the peptide binding groove. The TCR molecule recognizes the complex with the help of the CDR sequence in its binding domain and is expected to bind specifically. The binding of the TCR molecule to the pMHC complex is MHC-dependent, that is, the TCR molecule recognizes the pMHC complex while recognizing the antigenic peptide.
[0047] The term "T cell receptor (TCR)" refers to the functional unit of T lymphocytes recognizing antigens (pMHC), which belongs to the immunoglobulin superfamily. TCR expressed on T cells is a glycoprotein on the cell membrane surface that exists in the form of heterodimers of α chain / β chain or γ chain / δ chain. In the human body, the vast majority (90%-95%) of TCRs in peripheral blood are heterodimers composed of two polypeptide chains, α chain and β chain. Both α chain and β chain can be divided into variable region (Vα, Vβ), constant region (Cα, Cβ), transmembrane region and cytoplasmic region. The cytoplasmic region of α chain and β chain is very short, including only a few amino acids. The sequence variation of constant region (Cα, Cβ) is relatively small, and the specific amino acid sequence can be found, for example, in the public database of the International Immunogenetics Information System (IMGT). Positively charged amino acids are included in the transmembrane region to non-covalently bind to negatively charged amino acids in the transmembrane region of CD3 molecules to stabilize the structure of TCR-CD3 complex. The amino acid sequence analysis of the variable region of TCR shows that Vα and Vβ each have three hypervariable regions, called complementary determining regions (CDRs), namely CDR1, CDR2 and CDR3, among which CDR3 has the largest variation and largely determines the antigen specificity of TCR. In addition to the hypervariable regions, similar to antibody molecules, the variable region also includes four framework regions (FR1-FR4). The determination of the position of CDR1-CDR3 and FR1-FR4 in the full-length sequence of TCR is defined according to the IMGT nomenclature, which is well known and can be found in the IMGT public data. The variable regions in the α chain and the β chain, especially the three CDRs in the α chain and the three CDRs in the β chain, together form the part of TCR that specifically recognizes and binds to the pMHC complex (also referred to as the "binding domain" in this article). In the immune system, the binding of the antigen-specific TCR to the pMHC complex triggers direct physical contact between T cells and antigen presenting cells (APCs) or target cells to activate T cells or achieve a killing effect on target cells. Unless otherwise stated or implied by the context, when referring to a TCR the term may also encompass functional fragments thereof with antigen specificity, such as the Vα and Vβ variable regions connected by a short peptide.
[0048] The term "antibody" is used in its broadest sense herein, including immunoglobulins or other types of molecules comprising one or more antigen-binding domains that specifically bind to an antigen, and are proteins or polypeptides that exhibit binding specificity to a specific antigen. Specific examples of antibodies may include complete antibodies (e.g., classic four-chain antibody molecules), single-chain antibodies, single-domain antibodies, multispecific antibodies, and the like. Classical antibody molecules are typically tetramers composed of two identical heavy chains and two identical light chains interconnected by disulfide bonds. According to the conservative differences in the amino acid sequences, the heavy chain and the light chain are divided into a variable region (V) located at the amino terminus and a constant region (C) located at the carboxyl terminus. The variable region is used to recognize and bind to the antigen, and the constant region (e.g., Fc fragment) is used to initiate downstream effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC). In the variable regions of the heavy and light chains, there are three local regions, respectively, with a higher degree of variation in amino acid composition and arrangement order, which are key positions for antibody-antigen binding, and are therefore also referred to as complementary determining regions (CDRs). The three complementary determining regions of the heavy chain are respectively referred to as HCDR1, HCDR2 and HCDR3, and the three complementary determining regions of the light chain are respectively referred to as LCDR1, LCDR2 and LCDR3. Each heavy chain variable region (VH) and light chain variable region (VL) may be composed of three CDRs and four FR regions, which may be arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. Herein, the antibody molecule may also include a fusion protein recombined by recombining the variable region of the TCR molecule with the constant region of the antibody molecule, which has both the antigen specificity of the TCR molecule and the effector function of the constant region of the antibody molecule.
[0049] The term "chimeric antigen receptor (CAR)" refers to an engineered membrane protein receptor molecule that can confer desired specificity to immune effector cells, such as the ability to bind to specific tumor antigens. Chimeric antigen receptors are generally composed of an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. In some cases, the antigen binding domain is a scFv sequence or a single-domain antibody fragment responsible for recognizing and binding to a specific antigen. The intracellular signaling domain generally includes an immunoreceptor tyrosine activation motif (ITAM), such as a signaling domain derived from a CD3δ molecule, which is responsible for activating immune effector cells and producing a killing effect. In addition, the chimeric antigen receptor may also include a signal peptide responsible for the localization of the nascent protein in the cell at the amino terminus, and a hinge region between the antigen binding domain and the transmembrane domain. In addition to the signaling domain, the intracellular signaling domain may also include a costimulatory domain derived from, for example, a 4-1BB or CD28 molecule.
[0050] The terms "antigen specificity", "targeting" or "specific binding" refer to the property of TCR (or other fusion proteins including its binding domain, such as CAR) that can specifically recognize and bind to the corresponding pMHC complex with high affinity. TCR (or other fusion proteins including its binding domain, such as CAR) can have a higher binding affinity to another molecule (such as pMHC complex) for which it has antigen specificity relative to other molecules in the environment. The binding affinity of TCR to pMHC complex can be measured by some parameters, such as EC 50 value or KD value.
[0051] The term "binding protein" refers to a protein that has a specific binding ability to a specific ligand (such as an antigen). In this article, the binding protein may include a TCR molecule (including a single-chain TCR and a water-soluble TCR molecule) that has a specific binding ability to a pMHC complex, a fusion protein (antibody molecule or chimeric antigen receptor, etc.) formed by the TCR molecule and other proteins, and an immunoconjugate (connected with a detectable label, a therapeutic agent or a radioisotope, etc.).
[0052] The term "fusion protein" refers to a protein molecule composed of at least two different peptide segments that is artificially generated (e.g., by genetic engineering technology). These peptide segments do not exist in nature, or do not exist in the same protein molecule. Common examples of fusion proteins including antibody fragments include multispecific antibodies, antibody-cytokine fusion proteins, enzyme-labeled antibodies for immune detection, chimeric antigen receptors (CARs), etc.
[0053] When referring to TCR (or its antigen-specific fragment), the term "variant" as used herein refers to a protein obtained after introducing one or more amino acid insertions, deletions or substitutions on the basis of the parent TCR (or its antigen-specific fragment), which still retains at least part of the function of the parent TCR (or its antigen-specific fragment) (especially the function of interest, such as the ability to bind to the corresponding pMHC complex). For example, the variant of TCR (or its antigen-specific fragment) may retain at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of the binding ability of its parent TCR (or its antigen-specific fragment) to the pMHC complex, or even have a higher binding ability than the parent TCR (or its antigen-specific fragment). In some embodiments, the variant of TCR (or its antigen-specific fragment) may retain at least 80%, 85%, 90%, 95% or even 100% or more of the binding affinity of its parent TCR (or its antigen-specific fragment) to the antigen. Variants of TCR (or antigen-specific fragment thereof) generally include amino acid changes in the variable region framework sequence and / or constant region, but it does not exclude that one or a few amino acid changes may be made to the CDR region sequence. Therefore, those skilled in the art can also understand that, based on the specific TCR (or antigen-specific fragment thereof) amino acid sequence (CDR sequence, variable region sequence or α / β chain sequence) provided herein, a few amino acids can be replaced, deleted, added, and the binding ability or biological activity of the obtained product with the corresponding pMHC complex can be verified or screened, thereby obtaining the corresponding variants of the TCR (or antigen-specific fragment thereof) provided herein, and these variants should also be included in the scope of the present invention.
[0054] The terms "nucleic acid molecule", "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to a nucleotide polymer. Such nucleotide polymers may contain natural and / or non-natural nucleotides and include, but are not limited to, DNA, RNA and PNA. A "nucleic acid sequence" refers to a linear sequence of nucleotides contained in a nucleic acid molecule or polynucleotide.
[0055] The term "vector" refers to a nucleic acid molecule that can be engineered to contain a polynucleotide of interest (e.g., a coding sequence for a polypeptide of interest) or a nucleic acid molecule that can replicate in a host cell (e.g., a nucleic acid, a plasmid, or a virus, etc.). A vector may include one or more of the following components: an origin of replication, one or more regulatory sequences (such as a promoter and / or enhancer) that regulate the expression of the polynucleotide of interest, and / or one or more selectable marker genes (such as antibiotic resistance genes and genes that can be used in colorimetric analysis, such as β-galactose). The term "expression vector" refers to a vector used to express a polypeptide of interest in a host cell.
[0056] "Host cell" refers to a cell that can be or has been a recipient of a vector or isolated polynucleotide. The host cell can be a prokaryotic cell or a eukaryotic cell. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate cells; fungal cells, such as yeast; plant cells; and insect cells. Non-limiting exemplary mammalian cells include (but are not limited to) CHO cells, HEK-293 cells, BHK cells or PER-C6 cells, and their derivatives, such as 293-6E, CHO-DG44, CHO-K1, CHO-S and CHO-DS cells. In some embodiments, host cells are used to prepare target proteins, such as TCR α chains and / or β chains provided herein can be secreted and produced by mammalian cells. In other embodiments, host cells have specific functions after expressing TCR molecules provided herein, such as the ability to recognize and kill target cells expressing specific antigenic peptides after T cells express TCR molecules provided herein. Cells or cell lines from which host cells can be isolated also include cells transfected with nucleic acid molecules or expression vectors provided herein in vivo. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
[0057] "Subject" includes animals, such as mammals, including but not limited to primates, rodents, apes, felines, canines, equines, bovines, swine, sheep, goats, mammalian experimental animals, mammalian farm animals, mammalian sports animals and mammalian pets. The subject can be male or female and can be any age-appropriate subject, including infants, young children, youth, adults and elderly subjects. In some instances, the subject refers to an individual who needs to diagnose or treat a disease or illness. In some instances, the subject receiving diagnosis or treatment may be a patient who suffers from a disease associated with the diagnosis or treatment, or is at risk of suffering from the disease. In a specific instance, the subject is a human, such as a human patient. The term is usually used interchangeably with "patient", "test subject", "treatment subject" and the like.
[0058] When referring to pharmaceutical compositions, the term "pharmaceutically acceptable carrier" refers to solid or liquid diluents, fillers, antioxidants, stabilizers and the like that can be safely administered, are suitable for administration to humans and / or animals without excessive adverse side effects, and are suitable for maintaining the activity of the drugs or active agents contained therein.
[0059] When referring to disease treatment, "effective amount" refers to the amount of active molecules (such as antibodies) sufficient to cause the biological or medical response desired by the clinician in the subject. The "effective amount" at the time of administration can be determined by those skilled in the art based on factors such as the route of administration, the subject's weight, age, and condition. For example, for protein drugs, a typical daily dose range can be 0.01 mg to 100 mg of active ingredient per kg body weight. For immune effector cells (such as T cells) expressing the TCR provided herein, the number of cells administered per infusion can be, for example, from about 1×10 6 About 1×10 12 In some embodiments, the number of cells can vary from less than 1×10 6 The administration of active molecules (such as TCR, antibody, fusion protein) or immune effector cells provided herein includes, but is not limited to, injection, such as intravenous, intramuscular, intraarterial, subcutaneous, intraperitoneal, etc.
[0060] When referring to amino acid or nucleotide sequences, the term "sequence identity" (also referred to as "sequence identity") refers to the amount of consistency between two amino acid or nucleotide sequences (e.g., a query sequence and a reference sequence), generally expressed as a percentage. Usually, before calculating the percentage of consistency between two amino acid or nucleotide sequences, the sequences are aligned and gaps (if any) are introduced. If the amino acid residues or bases in the two sequences are the same at a certain alignment position, the two sequences are considered to be consistent or matched at that position; if the amino acid residues or bases in the two sequences are different, they are considered to be inconsistent or mismatched at that position. In some algorithms, the number of matching positions is divided by the total number of positions in the alignment window to obtain sequence consistency. In other algorithms, the number of gaps and / or the length of the gaps are also taken into account. For the purposes of the present invention, the publicly available alignment software BLAST (available on the webpage ncbi.nlm.nih.gov) can be used to obtain the best sequence alignment and calculate the sequence consistency between two amino acid or nucleotide sequences using the default settings. In some embodiments, the "at least 80% sequence identity" described herein includes, but is not limited to, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or even 100% sequence identity.
[0061] Provided herein are isolated or purified binding proteins, e.g., T cell receptors (TCRs), antibodies or CARs, that have antigenic specificity for an antigenic peptide (having amino acid mutation sites relative to the wild-type sequence)-MHC complex, wherein the antigenic peptide is derived from a mutant KRAS protein.
[0062] The present invention also provides polypeptides and proteins related to the TCR or its binding domain, as well as related nucleic acid molecules, vectors (such as recombinant expression vectors), host cells (such as T cells) and pharmaceutical compositions.
[0063] Also provided herein are methods and kits for detecting the presence of a tumor in a subject, as well as methods of treating or preventing a tumor in a subject.
[0064] T cell receptor (TCR)
[0065] Provided herein is an isolated or purified T cell receptor (TCR) having antigen specificity for an antigenic peptide (having an amino acid mutation site relative to the wild-type sequence)-MHC complex, wherein the antigenic peptide is derived from a mutant KRAS protein and comprises (1) VVGAVGVGK (SEQ ID NO: 91) or (2) VVVGAVGVGK (SEQ ID NO: 92), or is composed thereof. Considering that the MHC class I molecule is not strictly limited to the length of the antigenic peptide, the inventors expect that one or two amino acids can be added or deleted (especially at the end) on the basis of the above-mentioned antigenic peptide sequence provided herein, and the binding protein or TCR molecule provided herein also has the ability to bind to these antigenic peptide variant-MHC complexes.
[0066] The TCR provided herein can be an αβ heterodimer or a single-chain form (scTCR). Examples of single-chain forms can be αβTCR polypeptides in the form of Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ or Vα-L-Vβ-Cβ (wherein Vα and Vβ refer to TCRα chain and TCRβ chain variable regions, respectively, Cα and Cβ are TCRα chain constant regions and TCRβ chain constant regions, respectively, and L is a linker sequence, usually a short peptide). The linker sequence can be conventional in the art, and it is often used in antibody engineering and TCR engineering. The TCR provided herein can also be a water-soluble TCR molecule, which does not contain the transmembrane region of α and β chains.
[0067] In some embodiments, provided herein is a TCR having antigen specificity for the antigenic peptide VVGAVGVGK (SEQ ID NO: 91)-MHC complex or VVVGAVGVGK (SEQ ID NO: 92)-MHC complex. The CDR3 of the α chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 36, 45, 55, 65, 75, or 85, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 36, 45, 55, 65, 75, or 85; the CDR3 of the β chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence as shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90. Preferably, the MHC molecule is HLA-A*11:01.
[0068] Further, in the α chain variable region, CDR1 includes the amino acid sequence of SEQ ID NO: 3, CDR2 includes the amino acid sequence of SEQ ID NO: 3, and CDR3 includes the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; CDR1 includes the amino acid sequence of SEQ ID NO: 13, CDR2 includes the amino acid sequence of SEQ ID NO: 14, and CDR3 includes the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 15; CDR1 includes the amino acid sequence of SEQ ID NO: 23, CDR2 includes the amino acid sequence of SEQ ID NO: 24, and CDR3 includes the amino acid sequence of SEQ ID NO: 25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:25 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:25; CDR1 comprises the amino acid sequence of SEQ ID NO:33, CDR2 comprises the amino acid sequence of SEQ ID NO:34, and CDR3 comprises the amino acid sequence of SEQ ID NO:35, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:35; CDR1 comprises the amino acid sequence of SEQ ID NO:43, CDR2 comprises the amino acid sequence of SEQ ID NO:44, and CDR3 comprises the amino acid sequence of SEQ ID NO:45, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:45; CDR1 comprises the amino acid sequence of SEQ ID NO:53, CDR2 comprises the amino acid sequence of SEQ ID NO:54, and CDR3 comprises the amino acid sequence of SEQ ID NO:55, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:55. an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:55; CDR1 comprises the amino acid sequence of SEQ ID NO:63, CDR2 comprises the amino acid sequence of SEQ ID NO:64, and CDR3 comprises the amino acid sequence of SEQ ID NO:65, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:65;CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 75; or CDR1 comprises the amino acid sequence of SEQ ID NO: 83, CDR2 comprises the amino acid sequence of SEQ ID NO: 84, and CDR3 comprises the amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 85; in the beta chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:10 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:10; CDR1 comprises the amino acid sequence of SEQ ID NO:18, CDR2 comprises the amino acid sequence of SEQ ID NO:19, and CDR3 comprises the amino acid sequence of SEQ ID NO:20, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:20; CDR1 comprises the amino acid sequence of SEQ ID NO:28, CDR2 comprises the amino acid sequence of SEQ ID NO:29, and CDR3 comprises the amino acid sequence of SEQ ID NO:30, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:30; CDR1 comprises the amino acid sequence of SEQ ID NO:38, CDR2 comprises the amino acid sequence of SEQ ID NO:39, and CDR3 comprises the amino acid sequence of SEQ ID NO:40, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:41. an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:40; CDR1 comprises the amino acid sequence of SEQ ID NO:48, CDR2 comprises the amino acid sequence of SEQ ID NO:49, and CDR3 comprises the amino acid sequence of SEQ ID NO:50, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:50;CDR1 comprises the amino acid sequence of SEQ ID NO:58, CDR2 comprises the amino acid sequence of SEQ ID NO:59, and CDR3 comprises the amino acid sequence of SEQ ID NO:60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:60; CDR1 comprises the amino acid sequence of SEQ ID NO:68, CDR2 comprises the amino acid sequence of SEQ ID NO:69, and CDR3 comprises the amino acid sequence of SEQ ID NO:70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:70; CDR1 comprises the amino acid sequence of SEQ ID NO:78, CDR2 comprises the amino acid sequence of SEQ ID NO:79, and CDR3 comprises the amino acid sequence of SEQ ID NO:80, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:80; or CDR1 comprises SEQ ID NO: The amino acid sequence of SEQ ID NO: 88, CDR2 includes the amino acid sequence of SEQ ID NO: 89, and CDR3 includes the amino acid sequence of SEQ ID NO: 90, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, and more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO: 90.
[0069] Furthermore, in the TCR molecule, CDR1 in the α chain variable region includes the amino acid sequence shown in SEQ ID NO: 3, CDR2 includes the amino acid sequence shown in SEQ ID NO: 4, and CDR3 includes the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 5; CDR1 in the β chain variable region includes the amino acid sequence shown in SEQ ID NO: 8, CDR2 includes the amino acid sequence shown in SEQ ID NO: 9, and CDR3 includes the amino acid sequence shown in SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 10; CDR1 in the α chain variable region includes the amino acid sequence shown in SEQ ID NO: 13, CDR2 includes the amino acid sequence shown in SEQ ID NO: 14, and CDR3 includes the amino acid sequence shown in SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: NO:15, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:18, CDR2 comprises the amino acid sequence of SEQ ID NO:19, and CDR3 comprises the amino acid sequence of SEQ ID NO:20, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO:20; wherein CDR1 in the alpha chain variable region comprises the amino acid sequence of SEQ ID NO:23, CDR2 comprises the amino acid sequence of SEQ ID NO:24, and CDR3 comprises the amino acid sequence of SEQ ID NO:25, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO:25, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:28, CDR2 comprises the amino acid sequence of SEQ ID NO:29, and CDR3 comprises the amino acid sequence of SEQ ID NO:21. The amino acid sequence of SEQ ID NO:30, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:30;In the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 43, CDR2 comprises the amino acid sequence of SEQ ID NO: 44, and CDR3 comprises the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:45, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:48, CDR2 comprises the amino acid sequence of SEQ ID NO:49, and CDR3 comprises the amino acid sequence of SEQ ID NO:50, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:50; wherein CDR1 in the alpha chain variable region comprises the amino acid sequence of SEQ ID NO:53, CDR2 comprises the amino acid sequence of SEQ ID NO:54, and CDR3 comprises the amino acid sequence of SEQ ID NO:55, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:55, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:58, CDR2 comprises the amino acid sequence of SEQ ID NO:59, and CDR3 comprises the amino acid sequence of SEQ ID NO:50 NO:60, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:60;In the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:75, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:78, CDR2 comprises the amino acid sequence of SEQ ID NO:79, and CDR3 comprises the amino acid sequence of SEQ ID NO:80, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:80; or CDR1 in the alpha chain variable region comprises the amino acid sequence of SEQ ID NO:83, CDR2 comprises the amino acid sequence of SEQ ID NO:84, and CDR3 comprises the amino acid sequence of SEQ ID NO:85, or an amino acid sequence that has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:85, wherein CDR1 in the beta chain variable region comprises the amino acid sequence of SEQ ID NO:88, CDR2 comprises the amino acid sequence of SEQ ID NO:89, and CDR3 comprises the amino acid sequence of SEQ ID NO:80 The amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence shown in SEQ ID NO: 90. ;
[0070] In some specific embodiments, in the TCR molecule, the α chain comprises the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 1; the β chain comprises the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 6; the α chain comprises the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 11; the β chain comprises the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 16; the α chain comprises the amino acid sequence of SEQ ID NO: 21, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: NO:21 has at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity, the β chain includes the amino acid sequence of SEQ ID NO:26 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:26; the α chain includes the amino acid sequence of SEQ ID NO:31 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:31, the β chain includes the amino acid sequence of SEQ ID NO:36 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:36; the α chain includes the amino acid sequence of SEQ ID NO:41 or an amino acid sequence with at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:41, the β chain includes the amino acid sequence of SEQ ID NO: NO:46, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO:46;The α chain comprises the amino acid sequence of SEQ ID NO:51, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:51; the β chain comprises the amino acid sequence of SEQ ID NO:56, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:56; the α chain comprises the amino acid sequence of SEQ ID NO:61, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:61; the β chain comprises the amino acid sequence of SEQ ID NO:66, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:66; the α chain comprises the amino acid sequence of SEQ ID NO:71, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:71. NO:71, the β chain comprises the amino acid sequence of SEQ ID NO:76 or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO:76; or the α chain variable region comprises the amino acid sequence of SEQ ID NO:81 or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO:81, the β chain comprises the amino acid sequence of SEQ ID NO:86 or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity with the amino acid sequence of SEQ ID NO:86. ;
[0071] It will be appreciated by those skilled in the art that, based on the specific sequences provided herein, a small number of amino acids can be replaced, deleted, added, and the binding ability or biological activity of the resulting product to the corresponding pMHC complex can be verified or screened, thereby obtaining the corresponding variants of the TCR molecules provided herein, and these variants should also be included in the scope of the present invention. For example, the TCR molecules provided herein may have at least 1 and no more than 10, such as no more than 5, 4, 3, 2 or 1 amino acid changes in their full length or variable region sequence or CDR sequence. For example, there may be at least 1 and no more than 10, such as no more than 5, 4, 3, 2 or 1 amino acid changes in the α or β variable region sequence, and there may also be no more than 5, 4, 3, 2 or 1 amino acid changes in the CDR sequence of the α or β variable region.
[0072] It is contemplated that the TCRs described herein (or antigen-specific fragments thereof) may comprise conservative amino acid substitutions. Conservative amino acid substitutions may generally be described as substitutions of one amino acid residue by another amino acid residue of similar chemical structure, and having little or substantially no effect on the function, activity or other biological properties of the polypeptide. Conservative amino acid substitutions are well known in the art. Conservative substitutions may, for example, be substitutions of one amino acid in the following (a)-(e) groups by another amino acid in the same group: (a) small aliphatic non-polar or weakly polar residues: Ala, Ser, Thr, Pro and Gly; (b) polar negatively charged residues and their (uncharged) amides: Asp, Asn, Glu and Gln; (c) polar positively charged residues: His, Arg and Lys; (d) large aliphatic non-polar residues: Met, Leu, Ile, Val and Cys; and (e) aromatic residues: Phe, Tyr and Trp.
[0073] In some embodiments, the TCR (or its antigen-specific fragment) provided herein may further comprise post-translational modification. Examples of post-translational protein modifications include: phosphorylation, acetylation, methylation, ADP-ribosylation, ubiquitination, glycosylation, carbonylation, ubiquitination-like, biotinylation, or the addition of polypeptide side chains or hydrophobic groups. Therefore, the modified TCR (or its antigen-specific fragment) may comprise non-amino acid components, such as lipids, polysaccharides or monosaccharides, and phosphates. One form of glycosylation is, for example, sialylation modification, in which one or more sialic acid groups are bound to a polypeptide. Sialic acid groups improve the solubility and serum half-life of proteins, while also reducing the possible immunogenetic properties of proteins.
[0074] When the N-terminus of the amino acid sequence of the TCR provided herein is a methionine residue (M), as is well known to those skilled in the art, the methionine may be removed during the production process of the recombinant protein.
[0075] Fusion proteins and immunoconjugates
[0076] Also provided herein is a fusion protein comprising the variable region of the α chain and / or β chain of the TCR molecule provided herein, in particular the CDR sequence thereof.
[0077] In some embodiments, the fusion protein is in the form of a single-chain TCR. For example, the α chain variable region and the β chain variable region are connected by a linker sequence to form a complete binding domain with antigen specificity for the corresponding pMHC complex.
[0078] In some embodiments, the variable regions of the α chain and / or β chain of the TCR molecules provided herein, especially their CDR sequences, can be used to form TCR molecules with multi-specificity. In some embodiments, the fusion protein includes at least two functional parts, the first functional part has antigen specificity for the first pMHC complex, and the second functional part has the same or different antigen specificity as the first functional part.
[0079] In some embodiments, the variable regions of the α chain and / or β chain of the TCR molecules provided herein, especially their CDR sequences, can be used to form a fusion protein with multi-specificity. In some embodiments, the fusion protein includes at least two functional parts, the first functional part has antigen specificity for the pMHC complex, and the second functional part has antigen specificity or targeting different from the first functional part. In some embodiments, the second functional part can be a targeting part that can specifically recognize and bind to tumor-specific antigens, tumor-associated antigens or other target cell surface molecules, for example, antibodies or their antigen-binding fragments (e.g., scFv), hormones, growth factors, cytokines, and any other natural or non-natural ligands that can bind to cell surface receptors (e.g., epidermal growth factor receptor (EGFR), CD28, platelet-derived growth factor receptor (PDGFR), nicotinic acetylcholine receptor (nAChR), etc.).
[0080] In some embodiments, the binding domain of an antibody molecule (such as a classical tetrameric antibody molecule) can be replaced with a TCR molecule (or an α chain and β chain variable region or a binding domain formed thereof) provided herein to form a recombinant antibody molecule with the antigen specificity of the TCR molecule. In some embodiments, the two heavy chain variable regions of the antibody molecule are replaced with the α chain variable region of the TCR molecule and connected to the heavy chain constant region, and the two light chain variable regions of the antibody molecule are replaced with the β chain variable region and connected to the light chain constant region. In some embodiments, the two heavy chain variable regions of the antibody molecule are replaced with the β chain variable region of the TCR molecule and connected to the heavy chain constant region, and the two light chain variable regions of the antibody molecule are replaced with the α chain variable region and connected to the light chain constant region. In some embodiments, the α chain variable region and the β chain variable region of the TCR molecule are respectively replaced with a heavy chain variable region and a light chain variable region of the antibody molecule, and the original antigen binding domain of the antibody molecule is kept unchanged to form a recombinant antibody molecule with bispecificity, which targets the pMHC complex and the targeting antigen of the original antibody molecule respectively. The recombinant antibody molecule thus formed can realize the effector function of the antibody molecule through its constant region (such as Fc fragment), such as mediating complement dependent cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity (ADCC), mediating phagocytosis, etc. In addition, fusion with Fc fragment can increase the half-life of TCR molecule (or α chain and β chain variable region or the binding domain formed by them) in vivo, so as to increase the dosing interval when TCR molecule (or α chain and β chain variable region or the binding domain formed by them) is used as a therapeutic drug. In some embodiments, the Fc fragment can be derived from the constant region of immunoglobulin, such as IgG1, IgG2 or IgG4.
[0081] In some embodiments, the TCR molecules provided herein (or the α chain and β chain variable regions or the binding domains formed thereof) can be used as extracellular binding domains to construct chimeric antigen receptors (CAR). For example, the α chain and β chain variable regions can be connected by a linker sequence to form a binding molecule similar to scFv, replacing the extracellular binding domain in the conventional CAR molecule with the transmembrane region and the intracellular signaling domain. The CAR construct targets the pMHC complex corresponding to the original TCR molecule, and activates the T cells expressing the CAR through the intracellular conductive domain of the CAR molecule to achieve the desired immunological effect (e.g., target cell killing function).
[0082] In some embodiments, the TCR molecule (or the α chain and β chain variable regions or the binding domain formed therefrom) can be linked to a conjugate, such as a detectable label, therapeutic agent, tracer, etc., to form an immunoconjugate.
[0083] In some embodiments, the TCR molecule (or the α chain and β chain variable regions or the binding domain formed by them) can be connected to a protein tag to form a fusion protein. The protein tag may include a purification tag and a detectable tag. Purification tags include, but are not limited to, His6 tags, Flag tags, MBP tags, GST tags, SUMO tags, etc. The detectable tag can be used to indicate the presence or content of the TCR molecule (or the α chain and β chain variable regions or the binding domain formed by them) in the sample, or to track the location information of the TCR molecule (or the α chain and β chain variable regions or the binding domain formed by them) in the subject or in the cell. Examples of detectable tags include various enzymes that can be used in immunoassays, such as horseradish peroxidase (HRP), alkaline phosphatase (ALP), etc.; fluorescent proteins, such as GFP. Due to the specific binding ability of TCR molecules (or α chain and β chain variable regions or binding domains formed by them) to the corresponding pMHC complex, the amount of TCR molecules (or α chain and β chain variable regions or binding domains formed by them) can be determined by the amount of detectable labels connected to the TCR molecules (or α chain and β chain variable regions or binding domains formed by them), and then the content of the corresponding pMHC complex in the sample can be determined. When the corresponding pMHC complex can be used as a tumor marker, the fusion protein can be used for tumor detection and diagnosis.
[0084] In other embodiments, the TCR molecules (or the α chain and β chain variable regions or the binding domains formed therefrom) provided herein can be connected to cytokines or therapeutic proteins to form fusion proteins. In this case, the cytokines or therapeutic proteins can be purposefully delivered to specific tissues or cells by means of the specific binding ability of the TCR molecules (or the α chain and β chain variable regions or the binding domains formed therefrom) with the corresponding pMHC complexes, thereby achieving the therapeutic effects of the cytokines or therapeutic proteins.
[0085] In some embodiments, the TCR molecule (or the α chain and β chain variable regions or the binding domain formed therefrom) can be linked to a chemotherapeutic agent, such as asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc., so as to deliver the chemotherapeutic agent to specific cells or tissues through the antigen specificity of the TCR molecule.
[0086] In some embodiments, the TCR molecule (or the α chain and β chain variable regions or the binding domain formed thereof) can be combined with a radioactive isotope (e.g. 3 H. 14 C. 35 S) connection for tracking or therapeutic purposes.
[0087] Host cells expressing TCR molecules
[0088] Also provided herein are host cells expressing the TCR molecules (or the α chain and β chain variable regions or the binding domains formed thereof) provided herein.
[0089] The host cell used refers to any type of cell that can express the TCR molecules (or α chain and β chain variable regions or the binding domains formed thereof) provided herein. Preferably, the host cell expresses a complete TCR molecule, i.e., includes α chain and β chain variable regions, α chain and β chain constant regions, transmembrane regions and intracellular regions. The host cell can be a eukaryotic cell or a prokaryotic cell. Preferably, the host cell is preferably a mammalian cell. Most preferably, the host cell is a human cell. Although the host cell can be a cell of any cell type, can be derived from any type of tissue, and can be a cell of any developmental stage, the host cell is preferably a peripheral blood lymphocyte (PBL) or a peripheral blood mononuclear cell (PBMC). More preferably, the host cell is a T cell. For the purposes of this article, the T cell can be any T cell, such as a cultured T cell, for example, a primary T cell or a T cell from a cultured T cell line such as Jurkat, SupT1, etc., or a T cell obtained from a mammal. If obtained from a mammal, the T cell can be obtained from many sources, including but not limited to blood, bone marrow, lymph nodes, thymus or other tissues or fluids. T cells may also be enriched or purified. T cells may be any type of T cells and may be T cells at any developmental stage, including but not limited to: CD4+ / CD8+ double positive T cells, CD4+ helper T cells, such as Th1 and Th2 cells, CD4+T cells, CD8+T cells (e.g., cytotoxic T cells), tumor infiltrating lymphocytes (TILs), memory T cells (e.g., central memory T cells and effector memory T cells), naive T cells, etc.
[0090] Also provided herein is a host cell expressing the CAR provided herein. Preferably, the host cell is a human cell, especially a human T cell or a NK cell.
[0091] The utility function of host cells (such as T cells) expressing TCR or CAR can be detected in a variety of ways. In some embodiments, the host cells (such as T cells) expressing TCR or CAR are incubated with target cells, and the number or activity of target cells is detected to reflect the killing ability of host cells to target cells (such as by detecting the release of LDH). In some embodiments, the immune effect of host cells is assessed by incubating host cells (such as T cells) expressing TCR or CAR with target cells and detecting the secretion of IFN-γ or the expression of CD69 of host cells.
[0092] Pharmaceutical compositions and methods of treatment
[0093] The TCR molecules (or the α chain and β chain variable regions or the binding domains formed by them) provided herein and the fusion proteins or immunoconjugates comprising the TCR molecules (or the α chain and β chain variable regions or the binding domains formed by them) can be formulated as pharmaceutical compositions together with a pharmaceutically acceptable carrier and administered to a subject for tumor prevention or treatment.
[0094] In some embodiments, the TCR molecules (or the α chain and β chain variable regions or the binding domains formed by them) provided herein and fusion proteins or immunoconjugates comprising TCR molecules (or the α chain and β chain variable regions or the binding domains formed by them) can be administered in combination with one or more other drugs (e.g., anti-tumor agents).
[0095] In some embodiments, the disease or condition treated is a tumor, in particular a tumor expressing the antigenic peptide VVGAVGVGK (SEQ ID NO: 91) or VVVGAVGVGK (SEQ ID NO: 92). These tumors include, but are not limited to, acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer or rectal anal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder cancer or pleural cancer, nasal cancer, nasal cancer or middle ear cancer, oral cancer, vaginal cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, uterine ... Cervical cancer, gastrointestinal carcinoid tumors, gliomas, Hodgkin's lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, oropharyngeal cancer, ovarian cancer, penis cancer, pancreatic cancer, peritoneal cancer, omental cancer and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, ureter cancer and bladder cancer. Preferred cancers are pancreatic cancer, colorectal cancer, lung cancer, endometrial cancer, ovarian cancer, prostate cancer, etc.
[0096] Nucleic acid molecules encoding TCR molecules (or α chain and β chain variable regions or binding domains formed therefrom) provided herein and fusion proteins or immunoconjugates including TCR molecules (or α chain and β chain variable regions or binding domains formed therefrom), expression vectors including the nucleic acid molecules, and host cells (T cells, CAR cells) transfected with the nucleic acid molecules or expression vectors can also be used for the above-mentioned therapeutic purposes in various ways. For example, for expression vectors, gene therapy means known in the art can be introduced into the subject to express a target protein or polypeptide (e.g., TCR molecules (or α chain and β chain variable regions or binding domains formed therefrom) and fusion proteins or immunoconjugates including TCR molecules (or α chain and β chain variable regions or binding domains formed therefrom) provided herein), so as to achieve the therapeutic purpose.
[0097] The effective amount of this purpose can depend on the severity of the disease and the overall state of the patient's own immune system. The dosage regimen will also change with the disease state and the subject's state, and the general range will be from a single large amount of (bolus) administration or continuous infusion to multiple administrations per day (e.g., every 4-6 hours). Clinicians skilled in the art can, for example, easily determine whether a subject is a candidate for this treatment by utilizing clinical trials, physical examinations, and subject family history.
[0098] Test or treatment kit
[0099] The TCR molecules (or the α chain and β chain variable regions or the binding domain formed by them) provided herein and the fusion proteins or immunoconjugates comprising the TCR molecules (or the α chain and β chain variable regions or the binding domain formed by them) provided herein can specifically bind to the corresponding pMHC complex in the sample. By detecting the amount of the formed ternary complex (i.e., TCR-antigen peptide, MHC molecule), the content (or presence) of the corresponding pMHC complex in the sample can be conveniently determined.
[0100] As described above, for this purpose, the TCR molecules provided herein (or the α chain and β chain variable regions or the binding domains formed thereof) can be connected to various detection labels to facilitate detection by various means, including but not limited to bioluminescence, fluorescence, radioactive labeling, the production of products of enzymatic reactions, etc. After detecting the content of the corresponding pMHC complex in the sample, it can be compared with the normal corresponding pMHC complex content in the normal population, which can be used to determine the disease condition or severity of the subject providing the sample. By repeatedly detecting the changes in the content of the corresponding pMHC complex over time during the treatment of the subject, it can also be used to determine whether the treatment is effective, thereby providing a basis for changing the treatment plan.
[0101] The TCR molecules (or α chain and β chain variable regions or the binding domains formed thereof) provided herein and fusion proteins or immunoconjugates or host cells comprising TCR molecules (or α chain and β chain variable regions or the binding domains formed thereof) can be placed in containers to form detection or treatment kits. These containers can be boxes, ampoules, vials, tubes, bags or suitable container forms known in the art. These containers can be made of plastic, glass, laminated paper, metal foil or other materials suitable for storing drugs. If necessary, instructions for use are also provided with the container. The instructions may generally include information on how to use TCR molecules (or α chain and β chain variable regions or binding domains formed by them), compositions comprising TCR molecules (or α chain and β chain variable regions or binding domains formed by them), and host cells for treating or preventing tumors, and may include, for example, descriptions of therapeutic agents (such as TCR molecules (or α chain and β chain variable regions or binding domains formed by them), nucleic acid molecules, host cells, etc.); dosage regimens for treating or preventing neoplasia; precautions; warnings; indications; contraindications; adverse reactions; animal pharmacology; clinical studies; and / or reference materials. The instructions may be printed directly on the container (if present), or as a label affixed to the container, or as a separate paper, booklet, card, or folded printed matter provided in or with the container.
[0102] Experimental materials and reagents:
[0103] 1. Healthy human PBMC
[0104] 2. Targeted peptides:
[0105] A*11:01KRAS-G12V-9 peptide: VVGAVGVGK (SEQ ID NO: 91)
[0106] A*11:01KRAS-G12V-10 peptide: VVVGAVGVGK (SEQ ID NO: 92)
[0107] 3. Brilliant Violet 510 TM anti-human CD3 Antibody:Biolegend 300448
[0108] 4.APC anti-human CD8a Antibody:Biolegend 300912
[0109] 5.PE-KRAS-G12V-Pentamer:PROIMMUNE
[0110] 6.Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1
[0111] 7. Lentiviral vectors
[0112] 8. Polybrene Virus Enhancer: Merck Millipore TR-1003-G
[0113] 9.anti-CD3 / CD28 magnetic beads: novoprotein GMP-B038
[0114] 10.X-VIVO 15:lonza 04418q
[0115] 11.OKM-100:CansBio sj18
[0116] 12.RPMI 1640:gibco 11875-093
[0117] 13.LDH kit: dojindo
[0118] 14.Human IFN-γ kit: Excell Bio EH008-96
[0119] 15.IFN-γELISPOT:Mabtech 3420-4AST-10
[0120] 16.APC-anti-human CD69 Antibody:biolegend 310910
[0121] Instruments and Equipment
[0122] Flow cytometer: BD LSRFortessa
[0123] Flow sorter: SONY SH800S
[0124] Microplate reader: Molecular Devices SpectraMax i3x
[0125] ELISPOT imager: Bio-sys Bioreader BIO-SYS Bioreader 6000-Eβ
[0126] Graphics and analysis software
[0127] FlowJo
[0128] Graphpad Prism 8.0.1
[0129] Example
[0130] After T cells from three healthy donors were stimulated with dendritic cells loaded with mutant KRAS G12V 9 peptide (VVGAVGVGK) (SEQ ID NO: 91), the proportion of A*11:01-KRASG12V specific T cells was detected by pentamer staining and flow cytometry analyzer BD LSRFortessa, and then specific T cells were enriched and sorted by SONY SH800S flow sorter and analyzed by FlowJo software. The flow cytometric graph after analysis is shown in FIG. Figure 1 The enriched cells were subjected to 10× single-cell sequencing to obtain paired TCRα and TCRβ chains.
[0131] A lentiviral vector containing the TCR gene of the present invention was constructed and transduced into T cells. T cells transduced with different TCRs were respectively transduced with (1) different peptides (G12V-9 peptide: VVGAVGVGK (SEQ ID NO: 91), G12V-10 peptide: VVVGAVGVGK (SEQ ID NO: 92), WT peptide: VVGAGGVGK (SEQ ID NO: 93) +
[0132] VVVGAGGVGK (SEQ ID NO: 94)) expressing HLA-A*11:01 K562 cells and (2) expressing HLA-A*11:01, co-expressing HLA-A*11:01 and KRAS-G12V, and co-expressing HLA-A*11:01 and KRAS G12D BxPC3 cells (effector cells: target cells = 5:1) were co-incubated for 16 h, and the killing ability of different T cells on each target cell was evaluated by detecting the release of LDH. The data are shown in the table below. Figure 2A and 2B As shown (Graphpad Prism 8.0.1 software), T cells transduced with different TCRs have effective and specific killing effects on target cells expressing A*11:01 loaded with KRAS G12V-9 peptide or KRAS G12V-10 peptide and overexpressing KRAS G12V.
[0133] The release of IFN-γ after stimulation of T cells transduced with the specified TCR by KRAS G12V-9 peptide (VVGAVGVGK) (SEQ ID NO: 91) (effector cells: target cells = 1:1), as shown in Figure 3 As shown, primary T cells expressing the exemplary TCRs of the present disclosure produce large amounts of IFN-γ only upon target stimulation.
[0134] The EC50 of different TCRs was evaluated by the number of IFN-γ released spots and CD69 expression after T cells transduced with the specified TCRs were co-incubated with target cells loaded with different concentrations of KRAS G12V-9 peptide (VVGAVGVGK) (SEQ ID NO: 91), as shown in Figure 4A and 4B As shown, the EC50 concentration of TCR recognition of KRAS G12V-9 peptide is 1nM-10nM. Figure 4C As shown, the EC50 concentrations of TCR1 recognizing KRASG12V-9 peptide and 10 peptide differed by about 10 times, with the 9-peptide being 2.24 nM and the 10-peptide being 31.3 nM.
[0135] Some of the amino acid sequences mentioned herein are as follows.
[0136] TCR1α chain amino acid sequence
[0137] MRQVARVIVFLTLSTLSLAKTTQPISMDSYEGQEVNITCSHNNIATNDYITWYQQFPSQGPRFIIQGYKTKVTNEVASLFIPADRKSSTSLPRVSLSDTAVYYCLVGALSSSWYGQNFVFGPGTRLSVLPYIQNPDP AVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO:1)
[0138] TCR1α chain V region amino acid sequence
[0139] LAKTTQPISMDSYEGQEVNITCSHNNIATNDYITWYQQFPSQGPRFIIQGYKTKVTN EVASLFIPADRKSSTLSLPRVSLSDTAVYYCLVGALSSSWYGQNFVFGPGTRLSVLP(SEQ ID NO: 2)
[0140] TCR1α chain CDR1 amino acid sequence
[0141] NIATNDY (SEQ ID NO: 3)
[0142] TCR1α chain CDR2 amino acid sequence
[0143] GYKTK (SEQ ID NO: 4)
[0144] TCR1α chain CDR3 amino acid sequence
[0145] LVGALSSSWYGQNFV(SEQ ID NO: 5)
[0146] TCR1β chain amino acid sequence
[0147] MGCRLLCCVVFCLLQAGPLDTAVSQTPKYLVTQMGNDKSIKCEQNLGHDTMYWYKQDSKKFLKIMFSYNNKELIINETVPNRFSPKSPDKAHLNLHINSLELGDSAVYFCASSQSGAQDGYTFGSGTRLTVVEDLNKVFPPEVAVFEPSEAEISHT QKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO:6)
[0148] TCR1β chain V region amino acid sequence
[0149] DTAVSQTPKYLVTQMGNDKSIKCEQNLGHDTMYWYKQDSKKFLKIMFSYNNKELI INETVPNRFSPKSPDKAHLNLHINSLELGDSAVYFCASSQSGAQDGYTFGSGTRLTVV(SEQ ID NO: 7)
[0150] TCR1β chain CDR1 amino acid sequence
[0151] LGHDT (SEQ ID NO: 8)
[0152] TCR1β chain CDR2 amino acid sequence
[0153] YNNKEL (SEQ ID NO: 9)
[0154] TCR1β chain CDR3 amino acid sequence
[0155] ASSQSGAQDGYT (SEQ ID NO: 10)
[0156] TCR2 alpha chain amino acid sequence
[0157] MAMLLGASVLILWLQPDWVNSQQKNDDQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNEDGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAAKDNAGNMLTFGGGTRLMVKPHIQ NPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO:11)
[0158] TCR2α chain V region amino acid sequence
[0159] DQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNE DGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAAKDNAGNMLTFGGGTRLMVKP (SEQ ID NO: 12)
[0160] TCR2α chain CDR1 amino acid sequence
[0161] NSMFDY (SEQ ID NO: 13)
[0162] TCR2α chain CDR2 amino acid sequence
[0163] ISSIKDK (SEQ ID NO: 14)
[0164] TCR2α chain CDR3 amino acid sequence
[0165] AAKDNAGNMLT (SEQ ID NO: 15)
[0166] TCR2β chain amino acid sequence
[0167] MGSRLLCWVLLCLLGAGPVKAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRNKGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSLGTAEAFFGQGTRLTVVEDLNKVFPPEVAVFEPSEAEISHTQ KATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO:16)
[0168] TCR2β chain V region amino acid sequence
[0169] KAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRN KGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSLGTAEAFFGQGTRLTVV (SEQ ID NO: 17)
[0170] TCR2β-chain CDR1 amino acid sequence
[0171] SGHRS (SEQ ID NO: 18)
[0172] TCR2β-chain CDR2 amino acid sequence
[0173] YFSETQ (SEQ ID NO: 19)
[0174] TCR2β-chain CDR3 amino acid sequence
[0175] ASSLGTAEAF (SEQ ID NO: 20)
[0176] TCR3 alpha chain amino acid sequence
[0177] MAMLLGASVLILWLQPDWVNSQQKNDDQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNEDGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAANSGYALNFGKGTSLLVTPHIQN PDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO:21)
[0178] TCR3α chain V region amino acid sequence
[0179] DQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNE DGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAANSGYALNFGKGTSLLVTP (SEQ ID NO: 22)
[0180] TCR3α chain CDR1 amino acid sequence
[0181] NSMFDY (SEQ ID NO: 23)
[0182] TCR3α chain CDR2 amino acid sequence
[0183] ISSIKDK (SEQ ID NO: 24)
[0184] TCR3α chain CDR3 amino acid sequence
[0185] AANSGYALN (SEQ ID NO: 25)
[0186] TCR3β chain amino acid sequence
[0187] MGSRLLCWVLLCLLGAGPVKAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRNKGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSLGGVGNEQFFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQ KATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG(SEQ ID NO:26)
[0188] TCR3β chain V region amino acid sequence
[0189] KAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRN KGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSLGGVGNEQFFGPGTRLTVL (SEQ ID NO: 27)
[0190] TCR3β-chain CDR1 amino acid sequence
[0191] SGHRS (SEQ ID NO: 28)
[0192] TCR3β chain CDR2 amino acid sequence
[0193] YFSETQ (SEQ ID NO: 29)
[0194] TCR3β-chain CDR3 amino acid sequence
[0195] ASSLGGVGNEQF (SEQ ID NO: 30)
[0196] TCR4 alpha chain amino acid sequence
[0197] MMKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVERGSTLGRLYFGRGTQLTVWPDIQNP DPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO: 31)
[0198] TCR4α chain V region amino acid sequence
[0199] QKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKE DGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVERGSTLGRLYFGRGTQLTVWP (SEQ ID NO: 32)
[0200] TCR4α chain CDR1 amino acid sequence
[0201] DRGSQS (SEQ ID NO: 33)
[0202] TCR4α chain CDR2 amino acid sequence
[0203] IYSNGD (SEQ ID NO: 34)
[0204] TCR4α chain CDR3 amino acid sequence
[0205] AVERGSTLGRLY (SEQ ID NO: 35)
[0206] TCR4 β chain amino acid sequence
[0207] MGTSLLCWVVLGFLGTDSVSTDHTGAGVSQSPRYKVTKRGQDVTLRCDPISSHATLYWYQQALGQGPEFLTYFNYEAQPDKSGLPSDRFSAERPEGSISTLTIQRTEQRDSAMYRCASSLSSPTGGPINEQFFGPGTRLTVLEDLKNVFPPEVAVFEPSEAE ISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG(SEQ ID NO:36)
[0208] TCR4β chain V region amino acid sequence
[0209] GAGVSQSPRYKVTKRGQDVTLRCDPISSHATLYWYQQALGQGPEFLTYFNYEAQP DKSGLPSDRFSAERPEGSISTLTIQRTEQRDSAMYRCASSLSSPTGGPINEQFFGPGTRLTV L(SEQ ID NO: 37)
[0210] TCR4β-chain CDR1 amino acid sequence
[0211] SSHAT (SEQ ID NO: 38)
[0212] TCR4β-chain CDR2 amino acid sequence
[0213] FNYEAQ (SEQ ID NO: 39)
[0214] TCR4β-chain CDR3 amino acid sequence
[0215] ASSLSSPTGGPINEQF(SEQ ID NO:40)
[0216] TCR5α chain amino acid sequence
[0217] MKTFAGFSFLFLWLQLDCMSRGEDVEQSLFLSVREGDSSVINCTYTDSSSSTYLYWYKQEPGAGLQLLTYIFSNDMMKQDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAESPGGGADGLTFGKGTHLIIQPYIQNPD PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO: 41)
[0218] TCR5α chain V region amino acid sequence
[0219] GEDVEQSLFLSVREGDSSVINCTYTDSSSTYLYWYKQEPGAGLQLLTYIFSNDMMK QDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAESPGGGADGLTFGKGTHLIIQP (SEQ ID NO: 42)
[0220] TCR5α chain CDR1 amino acid sequence
[0221] DSSSTY (SEQ ID NO: 43)
[0222] TCR5α chain CDR2 amino acid sequence
[0223] IFSNMDM (SEQ ID NO: 44)
[0224] TCR5α chain CDR3 amino acid sequence
[0225] AESPGGGADGLT (SEQ ID NO: 45)
[0226] TCR5β chain amino acid sequence
[0227] MLLLLLLLGPGSGLGAVVSQHPSWVICKSGTSVKIECRSLDFQATTMFWYRQFPKQSLMLMATSNEGSKATYEQGVEKDKFLINHASLTLSTLTVTSAHPEDSSFYICSAPRGWAAGVYGYTFGSGTRLTVVEDLNKVFPPEVAVFEPSEAEISHT QKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO: 46)
[0228] TCR5β chain V region amino acid sequence
[0229] GAVVSQHPSWVICKSGTSVKIECRSLDFQATTMFWYRQFPKQSLMLMATSNEGSK ATYEQGVEKDKFLINHASLTLSTLTVTSAHPEDSSFYICSAPRGWAAGVYGYTFGSGTRL TVV(SEQ ID NO: 47)
[0230] TCR5β chain CDR1 amino acid sequence
[0231] DFQATT (SEQ ID NO: 48)
[0232] TCR5β chain CDR2 amino acid sequence
[0233] SNEGSKA (SEQ ID NO: 49)
[0234] TCR5β-chain CDR3 amino acid sequence
[0235] SAPRGWAAGVYGYT(SEQ ID NO:50)
[0236] TCR6 alpha chain amino acid sequence
[0237] MLLELIPLLGIHFVLRTARAQSVTQPDIHITVSEGASLELRCNYSYGATPYLFWYVQSPGQGLQLLKYFSGDTLVQGIKGFEAEFKRSQSSFNLRKPSVHWSDAAEYFCAVGASREYGNKLVFGAGTILRVKSYIQNP DPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO: 51)
[0238] TCR6α chain V region amino acid sequence
[0239] AQSVTQPDIHITVSEGASLELRCNYSYGATPYLFWYVQSPGQGLQLLLKYFSGDTL VQGIKGFEAEFKRSQSSFNLRKPSVHWSDAAEYFCAVGASREYGNKLVFGAGTILRVKS(SEQ ID NO: 52)
[0240] TCR6α chain CDR1 amino acid sequence
[0241] YGATPY (SEQ ID NO: 53)
[0242] TCR6α chain CDR2 amino acid sequence
[0243] YFSGDTLV (SEQ ID NO: 54)
[0244] TCR6α chain CDR3 amino acid sequence
[0245] AVGASREYGNKLV (SEQ ID NO: 55)
[0246] TCR6 β chain amino acid sequence
[0247] MDTRVLCCAVICLLGAGLSNAGVMQNPRHLVRRRGQEARLRCSPMKGHSHVYWYRQLPEEGLKFMVYLQKENIIDESGMPKERFSAEFPKEGPSILRIQQVVRGDSAAYFCASSPGGLLHFGNGTRLTVTEDLNKVFPPEVAVFEPSEAEISHTQ KATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO: 56)
[0248] TCR6β chain V region amino acid sequence
[0249] NAGVMQNPRHLVRRRGQEARLRCSPMKGHSHVYWYRQLPEEGLKFMVYLQKENI IDESGMPKERFSAEFPKEGPSILRIQQVVRGDSAAYFCASSPGGLLHFGNGTRLTVT (SEQ ID NO: 57)
[0250] TCR6β-chain CDR1 amino acid sequence
[0251] KGHSH (SEQ ID NO: 58)
[0252] TCR6β-chain CDR2 amino acid sequence
[0253] LQKENI (SEQ ID NO: 59)
[0254] TCR6β-chain CDR3 amino acid sequence
[0255] ASSPGGLLH (SEQ ID NO: 60)
[0256] TCR7 alpha chain amino acid sequence
[0257] MAMLLGASVLILWLQPDWVNSQQKNDDQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNEDGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAGKTNTGNQFYFGTGTSLTVIPNIQ NPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO: 61)
[0258] TCR7α chain V region amino acid sequence
[0259] DQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFLWYKKYPAEGPTFLISISSIKDKNE DGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAGKTNTGNQFYFGGTTSLTVIP (SEQ ID NO: 62)
[0260] TCR7α chain CDR1 amino acid sequence
[0261] NSMFDY (SEQ ID NO: 63)
[0262] TCR7α chain CDR2 amino acid sequence
[0263] ISSIKDK (SEQ ID NO: 64)
[0264] TCR7α chain CDR3 amino acid sequence
[0265] AGKTNTGNQFY (SEQ ID NO: 65)
[0266] TCR7 β chain amino acid sequence
[0267] MGSRLLCWVLLCLLGAGPVKAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRNKGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSSGHPEAFFGQGTRLTVVEDLNKVFPPEVAVFEPSEAEISHTQ KATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO: 66)
[0268] TCR7β chain V region amino acid sequence
[0269] KAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEYFSETQRN KGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSSGHPEAFFGQGTRLTVV (SEQ ID NO: 67)
[0270] TCR7β-chain CDR1 amino acid sequence
[0271] SGHRS (SEQ ID NO: 68)
[0272] TCR7β-chain CDR2 amino acid sequence
[0273] YFSETQ (SEQ ID NO: 69)
[0274] TCR7β-chain CDR3 amino acid sequence
[0275] ASSSGHPEAF (SEQ ID NO: 70)
[0276] TCR8 alpha chain amino acid sequence
[0277] METLLGVSLVILWLQLARVNSQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREKHSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDAGGGADGLTFGKGTHLIIQPYIQNPD PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO:71)
[0278] TCR8 α chain V region amino acid sequence
[0279] SQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREK HSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDAGGGADGLTFGKGTHLIIQP (SEQ ID NO: 72)
[0280] TCR8 α chain CDR1 amino acid sequence
[0281] TSINN (SEQ ID NO: 73)
[0282] TCR8 α chain CDR2 amino acid sequence
[0283] IRSNERE (SEQ ID NO: 74)
[0284] TCR8 α chain CDR3 amino acid sequence
[0285] ATDAGGGADGLT (SEQ ID NO: 75)
[0286] TCR8 β chain amino acid sequence
[0287] MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSESRDSGNTIYFGEGSWLTVVEDLNKVFPPEVAVFEPSEAEISHT QKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO:76)
[0288] TCR8β chain V region amino acid sequence
[0289] DSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERA KGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSESRDSGNTIYFGEGSWLTVV(SEQ ID NO: 77)
[0290] TCR8β-chain CDR1 amino acid sequence
[0291] SGDLS (SEQ ID NO: 78)
[0292] TCR8β-chain CDR2 amino acid sequence
[0293] YYNGEE (SEQ ID NO: 79)
[0294] TCR8 β chain CDR3 amino acid sequence
[0295] ASSESRDSGNTIY (SEQ ID NO: 80)
[0296] TCR9 alpha chain amino acid sequence
[0297] METLLGVSLVILWLQLARVNSQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREKHSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDSGGGADGLTFGKGTHLIIQPYIQNPD PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS(SEQ ID NO:81)
[0298] TCR9 α chain V region amino acid sequence
[0299] SQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREK HSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDSGGGADGLTFGKGTHLIIQP (SEQ ID NO: 82)
[0300] TCR9 α chain CDR1 amino acid sequence
[0301] TSINN (SEQ ID NO: 83)
[0302] TCR9α chain CDR2 amino acid sequence
[0303] IRSNERE (SEQ ID NO: 84)
[0304] TCR9 α chain CDR3 amino acid sequence
[0305] ATDSGGGADGLT (SEQ ID NO: 85)
[0306] TCR9 β chain amino acid sequence
[0307] MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASTPGRDSGNTIYFGEGSWLTVVEDLNKVFPPEVAVFEPSEAEISHT QKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF(SEQ ID NO:86)
[0308] TCR9β chain V region amino acid sequence
[0309] DSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERA KGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASTPGRDSGNTIYFGEGSWLTVV(SEQ ID NO: 87)
[0310] TCR9β-chain CDR1 amino acid sequence
[0311] SGDLS (SEQ ID NO: 88)
[0312] TCR9β-chain CDR2 amino acid sequence
[0313] YYNGEE (SEQ ID NO: 89)
[0314] TCR9β-chain CDR3 amino acid sequence
[0315] ASTPGRDSGNTIY (SEQ ID NO: 90).
Claims
1. A binding protein comprising a binding domain having antigen specificity for an antigen peptide:HLA complex, wherein the binding domain comprises a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, wherein: The antigenic peptide comprises the amino acid sequence VVGAVGVGK (SEQ ID NO: 91); The HLA is HLA-A*11:01; The CDR3 of the α chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, or 85, or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence as shown in SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, or 85; The CDR3 of the β chain variable region includes the amino acid sequence shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, or 90. 2 . The binding protein according to claim 1 , wherein the antigenic peptide is VVGAVGVGK (SEQ ID NO: 91) or VVVGAVGVGK (SEQ ID NO: 92).
3. The binding protein of claim 1, wherein in the α chain variable region: 1) CDR1 comprises the amino acid sequence of SEQ ID NO: 3, CDR2 comprises the amino acid sequence of SEQ ID NO: 4, and CDR3 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; 2) CDR1 comprises the amino acid sequence of SEQ ID NO: 13, CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and CDR3 comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 15; 3) CDR1 comprises the amino acid sequence of SEQ ID NO: 23, CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and CDR3 comprises the amino acid sequence of SEQ ID NO: 25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 25; 4) CDR1 comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; 5) CDR1 comprises the amino acid sequence of SEQ ID NO: 43, CDR2 comprises the amino acid sequence of SEQ ID NO: 44, and CDR3 comprises the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 45; 6) CDR1 comprises the amino acid sequence of SEQ ID NO: 53, CDR2 comprises the amino acid sequence of SEQ ID NO: 54, and CDR3 comprises the amino acid sequence of SEQ ID NO: 55, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 55; 7) CDR1 comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; 8) CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 75; or 9) CDR1 comprises the amino acid sequence of SEQ ID NO: 83, CDR2 comprises the amino acid sequence of SEQ ID NO: 84, and CDR3 comprises the amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 85, In the beta chain variable region: 1) CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 10; 2) CDR1 comprises the amino acid sequence of SEQ ID NO: 18, CDR2 comprises the amino acid sequence of SEQ ID NO: 19, and CDR3 comprises the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 20; 3) CDR1 comprises the amino acid sequence of SEQ ID NO: 28, CDR2 comprises the amino acid sequence of SEQ ID NO: 29, and CDR3 comprises the amino acid sequence of SEQ ID NO: 30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 30; 4) CDR1 comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; 5) CDR1 comprises the amino acid sequence of SEQ ID NO: 48, CDR2 comprises the amino acid sequence of SEQ ID NO: 49, and CDR3 comprises the amino acid sequence of SEQ ID NO: 50, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 50; 6) CDR1 comprises the amino acid sequence of SEQ ID NO: 58, CDR2 comprises the amino acid sequence of SEQ ID NO: 59, and CDR3 comprises the amino acid sequence of SEQ ID NO: 60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 60; 7) CDR1 comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; 8) CDR1 comprises the amino acid sequence of SEQ ID NO: 78, CDR2 comprises the amino acid sequence of SEQ ID NO: 79, and CDR3 comprises the amino acid sequence of SEQ ID NO: 80, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 80; or 9) CDR1 comprises the amino acid sequence shown in SEQ ID NO: 88, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 89, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO:
90.
4. The binding protein according to any one of claims 1 to 3, wherein: 1) In the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 3, CDR2 comprises the amino acid sequence of SEQ ID NO: 4, and CDR3 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 10; 2) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 13, CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and CDR3 comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 15; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 18, CDR2 comprises the amino acid sequence of SEQ ID NO: 19, and CDR3 comprises the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 20; 3) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 23, CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and CDR3 comprises the amino acid sequence of SEQ ID NO: 25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 25; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 28, CDR2 comprises the amino acid sequence of SEQ ID NO: 29, and CDR3 comprises the amino acid sequence of SEQ ID NO: 30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 30; 4) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; 5) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO:43, CDR2 comprises the amino acid sequence of SEQ ID NO:44, and CDR3 comprises the amino acid sequence of SEQ ID NO:45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:45; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO:48, CDR2 comprises the amino acid sequence of SEQ ID NO:49, and CDR3 comprises the amino acid sequence of SEQ ID NO:50, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:50; 6) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 53, CDR2 comprises the amino acid sequence of SEQ ID NO: 54, and CDR3 comprises the amino acid sequence of SEQ ID NO: 55, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 55; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 58, CDR2 comprises the amino acid sequence of SEQ ID NO: 59, and CDR3 comprises the amino acid sequence of SEQ ID NO: 60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 60; 7) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; 8) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 75; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 78, CDR2 comprises the amino acid sequence of SEQ ID NO: 79, and CDR3 comprises the amino acid sequence of SEQ ID NO: 80, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 80; or 9) In the α chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 83, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 84, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 85, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 85; in the β chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 88, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 89, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO:
90.
5. A binding protein comprising a binding domain, wherein the binding domain comprises a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, wherein: 1) In the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 3, CDR2 comprises the amino acid sequence of SEQ ID NO: 4, and CDR3 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 5; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 8, CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and CDR3 comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 10; 2) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 13, CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and CDR3 comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 15; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 18, CDR2 comprises the amino acid sequence of SEQ ID NO: 19, and CDR3 comprises the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 20; 3) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 23, CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and CDR3 comprises the amino acid sequence of SEQ ID NO: 25, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 25; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 28, CDR2 comprises the amino acid sequence of SEQ ID NO: 29, and CDR3 comprises the amino acid sequence of SEQ ID NO: 30, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 30; 4) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34, and CDR3 comprises the amino acid sequence of SEQ ID NO: 35, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 35; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and CDR3 comprises the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 40; 5) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO:43, CDR2 comprises the amino acid sequence of SEQ ID NO:44, and CDR3 comprises the amino acid sequence of SEQ ID NO:45, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:45; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO:48, CDR2 comprises the amino acid sequence of SEQ ID NO:49, and CDR3 comprises the amino acid sequence of SEQ ID NO:50, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO:50; 6) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 53, CDR2 comprises the amino acid sequence of SEQ ID NO: 54, and CDR3 comprises the amino acid sequence of SEQ ID NO: 55, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 55; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 58, CDR2 comprises the amino acid sequence of SEQ ID NO: 59, and CDR3 comprises the amino acid sequence of SEQ ID NO: 60, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 60; 7) CDR1 in the α chain variable region comprises the amino acid sequence of SEQ ID NO: 63, CDR2 comprises the amino acid sequence of SEQ ID NO: 64, and CDR3 comprises the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 65; CDR1 in the β chain variable region comprises the amino acid sequence of SEQ ID NO: 68, CDR2 comprises the amino acid sequence of SEQ ID NO: 69, and CDR3 comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 70; 8) in the α chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 73, CDR2 comprises the amino acid sequence of SEQ ID NO: 74, and CDR3 comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 75; in the β chain variable region, CDR1 comprises the amino acid sequence of SEQ ID NO: 78, CDR2 comprises the amino acid sequence of SEQ ID NO: 79, and CDR3 comprises the amino acid sequence of SEQ ID NO: 80, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 80; or 9) In the α chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 83, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 84, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 85, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 85; in the β chain variable region, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 88, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 89, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 90, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO:
90.
6. The binding protein according to any one of claims 1 to 5, wherein: 1) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 2; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 7; 2) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 12; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 17; 3) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 22; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 27, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 27; 4) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 32, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 32; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 37, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 37; 5) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 42, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 42; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 47, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 47; 6) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 52, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 52; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 57, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 57; 7) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 62, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 62; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 67; 8) the α chain variable region comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 72; the β chain variable region comprises the amino acid sequence of SEQ ID NO: 77, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 77; or 9) The α chain variable region comprises the amino acid sequence shown in SEQ ID NO: 82, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 82; the β chain variable region comprises the amino acid sequence shown in SEQ ID NO: 87, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO:
87.
7. The binding protein according to any one of claims 1 to 6, comprising the TCR α chain and the TCR β chain, wherein: 1) the α chain comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO: 1; the β chain comprises the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably 90% or 95% identity to the amino acid sequence of SEQ ID NO: 6; 2) the α chain comprises the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 11; the β chain comprises the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 16; 3) the α chain comprises the amino acid sequence of SEQ ID NO: 21, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 21; the β chain comprises the amino acid sequence of SEQ ID NO: 26, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 26; 4) the α chain comprises the amino acid sequence of SEQ ID NO: 31, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 31; the β chain comprises the amino acid sequence of SEQ ID NO: 36, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 36; 5) the α chain comprises the amino acid sequence of SEQ ID NO: 41, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 41; the β chain comprises the amino acid sequence of SEQ ID NO: 46, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 46; 6) the α chain comprises the amino acid sequence of SEQ ID NO: 51, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 51; the β chain comprises the amino acid sequence of SEQ ID NO: 56, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 56; 7) the α chain comprises the amino acid sequence of SEQ ID NO: 61, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 61; the β chain comprises the amino acid sequence of SEQ ID NO: 66, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 66; 8) the α chain comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 71; the β chain comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably 90% or 95% identical to the amino acid sequence of SEQ ID NO: 76; or 9) The α chain variable region comprises the amino acid sequence shown in SEQ ID NO: 81, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO: 81; the β chain comprises the amino acid sequence shown in SEQ ID NO: 86, or an amino acid sequence that is at least 80% identical, preferably at least 85% identical, and more preferably 90% or 95% identical to the amino acid sequence shown in SEQ ID NO:
86.
8. The binding protein according to any one of claims 1 to 7, which is in the form of: 1) TCR molecules; 2) Antibody molecules; or 3) CAR molecule.
9. The binding protein of any one of claims 1 to 8, wherein when T cells expressing the binding protein are incubated with HLA-A*11:01 cells in the presence of the antigenic peptide, or when T cells expressing the binding protein are incubated with HLA-A*11:01 cells expressing the antigenic peptide, the T cells specifically kill the HLA-A*11:01 cells.
10. The binding protein of any one of claims 1 to 9, wherein when T cells expressing the binding protein are incubated with HLA-A*11:01 cells in the presence of the antigenic peptide, or when T cells expressing the binding protein are incubated with HLA-A*11:01 cells expressing the antigenic peptide, the T cells produce INF-γ and / or express CD69, or the amount of INF-γ produced and / or CD69 expressed is increased.
11. The binding protein according to any one of claims 1 to 10, further comprising a conjugate covalently or non-covalently linked to the binding domain; preferably, the conjugate is a detectable marker, a radioactive isotope or a therapeutic agent.
12. An isolated nucleic acid molecule encoding the binding protein, α chain variable region, β chain variable region, α chain or β chain of any one of claims 1 to 11.
13. A vector comprising the nucleic acid molecule of claim 12.
14. A host cell expressing the binding protein according to any one of claims 1 to 11 or comprising the nucleic acid molecule according to claim 12 or the vector according to claim 13.
15. The host cell according to claim 14, which is a mammalian cell, preferably a human cell.
16. The host cell according to claim 14 or 15, which is a T cell or a NK cell.
17. The host cell according to any one of claims 14 to 16, which has killing activity against HLA-A*11:01 cells expressing the antigenic peptide VVGAVGVGK (SEQ ID NO: 91) or VVVGAVGVGK (SEQ ID NO: 92).
18. A pharmaceutical composition comprising: 1) the binding protein according to any one of claims 1 to 11, the nucleic acid molecule according to claim 12, the vector according to claim 13, or the host cell according to any one of claims 14 to 17; and 2) Pharmaceutically acceptable carrier.
19. Use of the binding protein according to any one of claims 1 to 11, the nucleic acid molecule according to claim 12, the vector according to claim 13 or the host cell according to any one of claims 14 to 17 in the preparation of a medicament for treating a tumor, wherein the tumor expresses the antigenic peptide.
20. A method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of the binding protein of any one of claims 1-11, the nucleic acid molecule of claim 12, the vector of claim 13, the cell of any one of claims 14-17, or the pharmaceutical composition of claim 18.
21. The use of claim 19 or the method of claim 20, wherein the tumor is selected from pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer, endometrial cancer and ovarian cancer.
22. A detection kit comprising the binding protein according to any one of claims 1 to 11.
Citation Information
Cited By
TCR molecule targeting KRAS g12v mutation, cell, and uses thereof
EP4660206A1
